United Historical Balance Sheet

UTHR Stock

USD 276.26 1.13 0.41%

Trend analysis of United Therapeutics balance sheet accounts such as Total Assets of 7.5 B, Short Long Term Debt Total of 735 M, Other Current Liabilities of 116.3 M or Total Current Liabilities of 844.6 M provides information on United Therapeutics' total assets, liabilities, and equity, which is the actual value of United Therapeutics to its prevalent stockholders. By breaking down trends over time using United Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining United Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether United Therapeutics is a good buy for the upcoming year.

United Therapeutics Inventory

55.95 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.

About United Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of United Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. United Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of United Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which United currently owns. An asset can also be divided into two categories, current and non-current.

United Therapeutics Balance Sheet Chart

At this time, United Therapeutics' Accounts Payable is relatively stable compared to the past year. As of 06/04/2024, Cash is likely to grow to about 1.3 B, while Non Currrent Assets Other are likely to drop slightly above 91.5 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Preferred Stock Total Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of United Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in United Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on United Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of United Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from United Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into United Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.At this time, United Therapeutics' Accounts Payable is relatively stable compared to the past year. As of 06/04/2024, Cash is likely to grow to about 1.3 B, while Non Currrent Assets Other are likely to drop slightly above 91.5 M.

	2023	2024 (projected)
Short and Long Term Debt Total	700M	735M
Total Assets	7.2B	7.5B

Short Long Term Debt Total Total Assets

United Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Good Will	Common Stock Total Equity	Short Term Investments	Property Plant And Equipment Gross	Short Term Debt	Intangible Assets
Total Assets		0.84	0.24	0.64	1.0	0.97	-0.14	0.97	-0.22	0.85	0.99	0.33	0.92	0.74	0.24	0.56	0.89	-0.3	0.89	0.99	0.92	0.46	0.95	0.99	0.83	0.48
Short Long Term Debt Total	0.84		0.27	0.37	0.8	0.8	0.26	0.8	-0.25	0.61	0.86	0.2	0.9	0.43	0.13	0.82	0.77	-0.3	0.92	0.8	0.84	0.4	0.82	0.79	0.82	0.51
Other Current Liab	0.24	0.27		-0.24	0.22	0.23	-0.18	0.33	0.02	0.33	0.21	0.54	0.42	0.44	0.08	0.51	0.29	-0.55	0.27	0.26	0.23	0.39	0.14	0.19	0.4	0.09
Total Current Liabilities	0.64	0.37	-0.24		0.63	0.69	-0.31	0.57	-0.19	0.61	0.63	0.23	0.36	0.69	0.45	-0.09	0.56	0.02	0.58	0.62	0.48	0.42	0.53	0.65	0.47	0.24
Total Stockholder Equity	1.0	0.8	0.22	0.63		0.96	-0.19	0.98	-0.22	0.86	0.98	0.33	0.9	0.74	0.2	0.51	0.88	-0.31	0.85	0.99	0.91	0.42	0.95	0.99	0.81	0.47
Property Plant And Equipment Net	0.97	0.8	0.23	0.69	0.96		-0.18	0.94	-0.15	0.85	0.96	0.43	0.86	0.79	0.4	0.53	0.84	-0.31	0.9	0.96	0.92	0.61	0.88	0.96	0.82	0.55
Net Debt	-0.14	0.26	-0.18	-0.31	-0.19	-0.18		-0.26	0.12	-0.59	-0.04	-0.57	-0.01	-0.58	-0.1	0.39	-0.16	0.41	0.12	-0.23	-0.01	-0.27	0.06	-0.17	0.13	0.03
Retained Earnings	0.97	0.8	0.33	0.57	0.98	0.94	-0.26		-0.28	0.91	0.94	0.49	0.92	0.78	0.11	0.54	0.91	-0.5	0.83	0.98	0.92	0.45	0.89	0.94	0.75	0.54
Accounts Payable	-0.22	-0.25	0.02	-0.19	-0.22	-0.15	0.12	-0.28		-0.3	-0.19	-0.14	-0.3	-0.21	0.41	-0.11	-0.33	0.34	-0.2	-0.26	-0.13	0.06	-0.2	-0.2	0.02	0.05
Cash	0.85	0.61	0.33	0.61	0.86	0.85	-0.59	0.91	-0.3		0.79	0.63	0.77	0.86	0.2	0.35	0.8	-0.56	0.69	0.89	0.74	0.54	0.68	0.83	0.57	0.41
Non Current Assets Total	0.99	0.86	0.21	0.63	0.98	0.96	-0.04	0.94	-0.19	0.79		0.27	0.9	0.69	0.26	0.58	0.84	-0.25	0.91	0.95	0.92	0.44	0.93	0.97	0.86	0.49
Non Currrent Assets Other	0.33	0.2	0.54	0.23	0.33	0.43	-0.57	0.49	-0.14	0.63	0.27		0.37	0.66	0.07	0.21	0.42	-0.86	0.31	0.38	0.44	0.65	0.12	0.26	0.14	0.57
Cash And Short Term Investments	0.92	0.9	0.42	0.36	0.9	0.86	-0.01	0.92	-0.3	0.77	0.9	0.37		0.61	0.11	0.79	0.88	-0.44	0.9	0.91	0.89	0.45	0.89	0.88	0.76	0.44
Net Receivables	0.74	0.43	0.44	0.69	0.74	0.79	-0.58	0.78	-0.21	0.86	0.69	0.66	0.61		0.39	0.21	0.73	-0.48	0.63	0.77	0.59	0.64	0.54	0.74	0.56	0.26
Common Stock Shares Outstanding	0.24	0.13	0.08	0.45	0.2	0.4	-0.1	0.11	0.41	0.2	0.26	0.07	0.11	0.39		0.12	0.08	0.36	0.39	0.22	0.13	0.7	0.16	0.31	0.4	-0.07
Non Current Liabilities Total	0.56	0.82	0.51	-0.09	0.51	0.53	0.39	0.54	-0.11	0.35	0.58	0.21	0.79	0.21	0.12		0.53	-0.32	0.75	0.53	0.62	0.43	0.58	0.5	0.6	0.35
Other Current Assets	0.89	0.77	0.29	0.56	0.88	0.84	-0.16	0.91	-0.33	0.8	0.84	0.42	0.88	0.73	0.08	0.53		-0.46	0.81	0.92	0.8	0.4	0.86	0.86	0.65	0.39
Other Stockholder Equity	-0.3	-0.3	-0.55	0.02	-0.31	-0.31	0.41	-0.5	0.34	-0.56	-0.25	-0.86	-0.44	-0.48	0.36	-0.32	-0.46		-0.25	-0.35	-0.44	-0.29	-0.14	-0.21	-0.07	-0.54
Total Liab	0.89	0.92	0.27	0.58	0.85	0.9	0.12	0.83	-0.2	0.69	0.91	0.31	0.9	0.63	0.39	0.75	0.81	-0.25		0.85	0.84	0.59	0.83	0.86	0.82	0.46
Total Current Assets	0.99	0.8	0.26	0.62	0.99	0.96	-0.23	0.98	-0.26	0.89	0.95	0.38	0.91	0.77	0.22	0.53	0.92	-0.35	0.85		0.89	0.46	0.94	0.97	0.78	0.45
Good Will	0.92	0.84	0.23	0.48	0.91	0.92	-0.01	0.92	-0.13	0.74	0.92	0.44	0.89	0.59	0.13	0.62	0.8	-0.44	0.84	0.89		0.46	0.88	0.88	0.76	0.73
Common Stock Total Equity	0.46	0.4	0.39	0.42	0.42	0.61	-0.27	0.45	0.06	0.54	0.44	0.65	0.45	0.64	0.7	0.43	0.4	-0.29	0.59	0.46	0.46		0.3	0.46	0.46	0.32
Short Term Investments	0.95	0.82	0.14	0.53	0.95	0.88	0.06	0.89	-0.2	0.68	0.93	0.12	0.89	0.54	0.16	0.58	0.86	-0.14	0.83	0.94	0.88	0.3		0.94	0.81	0.42
Property Plant And Equipment Gross	0.99	0.79	0.19	0.65	0.99	0.96	-0.17	0.94	-0.2	0.83	0.97	0.26	0.88	0.74	0.31	0.5	0.86	-0.21	0.86	0.97	0.88	0.46	0.94		0.82	0.37
Short Term Debt	0.83	0.82	0.4	0.47	0.81	0.82	0.13	0.75	0.02	0.57	0.86	0.14	0.76	0.56	0.4	0.6	0.65	-0.07	0.82	0.78	0.76	0.46	0.81	0.82		0.35
Intangible Assets	0.48	0.51	0.09	0.24	0.47	0.55	0.03	0.54	0.05	0.41	0.49	0.57	0.44	0.26	-0.07	0.35	0.39	-0.54	0.46	0.45	0.73	0.32	0.42	0.37	0.35

Click cells to compare fundamentals

United Therapeutics Account Relationship Matchups

United Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	3.9B	4.6B	5.2B	6.0B	7.2B	7.5B
Other Current Liab	39.6M	319.2M	301.6M	339.1M	71M	116.3M
Total Current Liabilities	463M	323.3M	305.4M	343.2M	804.4M	844.6M
Total Stockholder Equity	2.8B	3.4B	4.0B	4.8B	6.0B	6.3B
Property Plant And Equipment Net	738.5M	731.6M	780.9M	861.5M	1.0B	1.1B
Net Debt	111.6M	61.3M	(94.8M)	(161.2M)	(507.7M)	(482.3M)
Retained Earnings	3.3B	3.8B	4.3B	5.0B	6.0B	6.3B
Accounts Payable	23.1M	9.9M	4.1M	3.8M	5.6M	10.2M
Cash	738.4M	738.7M	894.8M	961.2M	1.2B	1.3B
Non Current Assets Total	2.0B	2.4B	2.8B	2.7B	3.6B	3.8B
Non Currrent Assets Other	154.6M	169.9M	108.2M	114.3M	151.8M	91.5M
Cash And Short Term Investments	2.3B	3.0B	3.6B	4.2B	3.0B	3.1B
Net Receivables	151.4M	157.4M	198.7M	220.4M	278.9M	292.8M
Common Stock Shares Outstanding	43.8M	44.6M	47.3M	48.5M	49.7M	50.7M
Liabilities And Stockholders Equity	3.9B	4.6B	5.2B	6.0B	7.2B	7.5B
Non Current Liabilities Total	670M	896.5M	904.8M	904.6M	377.8M	269.4M
Other Current Assets	133.8M	88.3M	100.4M	219.2M	166.2M	174.5M
Other Stockholder Equity	(531.3M)	(430.5M)	(333.8M)	(190.8M)	(30.2M)	(28.7M)
Total Liab	1.1B	1.2B	1.2B	1.2B	1.2B	1.2B
Total Current Assets	1.9B	2.2B	2.3B	3.4B	3.6B	3.7B
Short Term Investments	747.5M	1.1B	1.0B	1.9B	1.8B	1.9B
Property Plant And Equipment Gross	738.5M	731M	1.1B	1.2B	1.5B	1.5B
Intangible Assets	130.3M	130.1M	16.6M	16.5M	80.5M	84.5M
Other Liab	67M	79.4M	104.8M	76.8M	88.3M	60.5M
Other Assets	293.8M	1.6B	370.1M	413.5M	475.5M	284.7M
Inventory	93.4M	86.5M	93.8M	102M	111.8M	55.9M
Property Plant Equipment	738.5M	731.6M	780.9M	861.5M	990.7M	1.0B
Net Tangible Assets	2.6B	3.2B	3.9B	4.8B	5.5B	5.7B
Retained Earnings Total Equity	3.3B	3.8B	4.3B	5.0B	5.8B	6.1B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

United Historical Balance Sheet

United Therapeutics Inventory

55.95 Million

About United Balance Sheet Analysis

United Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

United Therapeutics balance sheet Correlations

United Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

United Therapeutics balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Additional Tools for United Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Stockholder Equity
Property Plant And Equipment Gross	+ 0.99	Total Stockholder Equity

Other Stockholder Equity	- 0.86	Non Currrent Assets Other
Cash	- 0.59	Net Debt
Net Receivables	- 0.58	Net Debt
Non Currrent Assets Other	- 0.57	Net Debt
Other Stockholder Equity	- 0.56	Cash
Other Stockholder Equity	- 0.55	Other Current Liab